BR112014018374A8 - Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica - Google Patents

Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica

Info

Publication number
BR112014018374A8
BR112014018374A8 BR112014018374A BR112014018374A BR112014018374A8 BR 112014018374 A8 BR112014018374 A8 BR 112014018374A8 BR 112014018374 A BR112014018374 A BR 112014018374A BR 112014018374 A BR112014018374 A BR 112014018374A BR 112014018374 A8 BR112014018374 A8 BR 112014018374A8
Authority
BR
Brazil
Prior art keywords
cancer
antibody
kit
treatment
patient
Prior art date
Application number
BR112014018374A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014018374A2 (ko
Inventor
Gerdes Christian
Gimmi Claude
Manenti Luigi
Umana Pablo
Rueger Ruediger
Hollingsworth Simon
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of BR112014018374A2 publication Critical patent/BR112014018374A2/pt
Publication of BR112014018374A8 publication Critical patent/BR112014018374A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
BR112014018374A 2012-03-02 2012-03-02 Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica BR112014018374A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/053600 WO2013127465A1 (en) 2012-03-02 2012-03-02 Predicitive biomarker for cancer treatment with adcc enhanced antibodies

Publications (2)

Publication Number Publication Date
BR112014018374A2 BR112014018374A2 (ko) 2017-06-20
BR112014018374A8 true BR112014018374A8 (pt) 2017-07-11

Family

ID=45814493

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018374A BR112014018374A8 (pt) 2012-03-02 2012-03-02 Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica

Country Status (8)

Country Link
JP (1) JP2015511702A (ko)
KR (1) KR20140130455A (ko)
AU (1) AU2012371260A1 (ko)
BR (1) BR112014018374A8 (ko)
CA (1) CA2860369A1 (ko)
MX (1) MX2014010379A (ko)
RU (1) RU2014138586A (ko)
WO (1) WO2013127465A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
SG11201609014TA (en) * 2014-05-08 2016-12-29 Chugai Pharmaceutical Co Ltd Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2017002934A1 (ja) * 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2574993T3 (es) 2003-01-22 2016-06-23 Roche Glycart Ag Construcciones de fusión y uso de las mismas para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
NZ556286A (en) 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
ATE501436T1 (de) * 2006-09-13 2011-03-15 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
AR075982A1 (es) * 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EP2513336B1 (en) * 2009-12-16 2016-03-02 Hitachi Chemical Co., Ltd. Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers

Also Published As

Publication number Publication date
MX2014010379A (es) 2015-05-15
WO2013127465A1 (en) 2013-09-06
BR112014018374A2 (ko) 2017-06-20
JP2015511702A (ja) 2015-04-20
RU2014138586A (ru) 2016-04-20
KR20140130455A (ko) 2014-11-10
AU2012371260A8 (en) 2014-09-18
AU2012371260A1 (en) 2014-07-10
CA2860369A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
CU20160101A7 (es) Inmunoglobulina con fab en tándem
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
TN2015000396A1 (en) Antibody drug conjugates
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
BR112014019861A2 (pt) anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
BR112013004673A2 (pt) biomarcadores e métodos de tratamento.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
CY1121821T1 (el) Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
UY35136A (es) Métodos para tratar el cáncer de ovario con antagonistas de dll4.
EA201490180A1 (ru) Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
EA201591304A1 (ru) Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
UA84044U (ru) Способ прогнозирования чувствительности к неоадьювантной терапии у больных раком молочной железы
WO2014150819A3 (en) Cancer biomarkers and methods of treating cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]